mTOR Inhibitor Blocks Prostate Cancer Metastasis in Preclinical Model

Share this content:

(ChemotherapyAdvisor) – Investigators have characterized how pro-invasion messenger RNAs direct prostate cancer invasion and metastasis downstream of oncogenic mTOR signaling — and then developed a clinically relevant ATP site inhibitor of mTOR, INK128, “which reprograms this gene expression signature with therapeutic benefit for prostate cancer metastasis, for which there is presently no cure,” they noted in Nature, published online February 22.

“Many human cancers show hyperactivation of this pathway,” said Davide Ruggero, PhD, of the Helen Diller Family Comprehensive Cancer Center and the Multiple Myeloma Translational Initiative at UCSF. “Until now, we have not known how hyperactive mTOR perturbs the synthesis of certain proteins leading to fatal cancer.”

This work using ribosome profiling helps pinpoint why, in the past, drugs that target mTOR, such as rapamycin, have failed in clinical trials: They may block mTOR, but not completely. Preclinical research with INK128 has found that a mouse model of human prostate cancer treated with the agent did not metastasize and also demonstrated a strong therapeutic effect on human prostate-cancer cells.

INK128, now in clinical trials for different types of cancers, including multiple myeloma, is being developed by Intellikine, Inc., La Jolla, CA.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs